| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | PFE | Common Stock | Options Exercise | $315,148 | +11,527 | +50% | $27.34 | 34,604 | 23 Feb 2024 | Direct | F1 |
| transaction | PFE | Common Stock | Tax liability | $25,123 | -905 | -2.6% | $27.76 | 33,699 | 23 Feb 2024 | Direct | F2 |
| transaction | PFE | Common Stock | Tax liability | $254,924 | -9,314 | -28% | $27.37 | 24,385 | 23 Feb 2024 | Direct | F3, F4 |
| holding | PFE | Common Stock | 11,405 | 23 Feb 2024 | By Rule 16b-3 Plan |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | PFE | Stock Appreciation Rights | Options Exercise | $0 | -11,527 | -100% | $0.000000* | 0 | 23 Feb 2024 | Common Stock | 11,527 | $27.34 | Direct |
| Id | Content |
|---|---|
| F1 | The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). |
| F2 | The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. |
| F3 | The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). |
| F4 | Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. |